Misplaced Pages

BGR-34: Difference between revisions

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Browse history interactively← Previous editNext edit →Content deleted Content addedVisualWikitext
Revision as of 20:03, 8 January 2019 editCwmhiraeth (talk | contribs)Autopatrolled, Administrators138,707 edits Correction← Previous edit Revision as of 12:50, 9 January 2019 edit undoWinged Blades of Godric (talk | contribs)Autopatrolled, Extended confirmed users, Pending changes reviewers, Rollbackers40,041 edits // Edit via Wikiplus/Remove inaccuraciesNext edit →
Line 1: Line 1:
{{short description|An Ayurvedic drug in India that supposedly treats Diabetes mellitus type 2}} {{short description|An Ayurvedic drug in India that supposedly treats Diabetes mellitus type 2}}
'''BGR-34''' (Blood Glucose Regulator 34<ref>{{Cite web|url=https://www.thehindubusinessline.com/news/science/2-years-on-markets-still-hypo-about-herbal-diabetes-drug/article8199206.ece|title=2 years on, markets still hypo about herbal diabetes drug|last=Somasekhar|first=M.|website=@businessline|language=en|access-date=2018-12-15}}</ref>) is an ] drug, sold as prescription drug in India for management of ]. It was developed by two government-laboratories over the decade, TOT was given in 2014 and commercially launched in October, 2015. '''BGR-34''' (Blood Glucose Regulator 34<ref>{{Cite web|url=https://www.thehindubusinessline.com/news/science/2-years-on-markets-still-hypo-about-herbal-diabetes-drug/article8199206.ece|title=2 years on, markets still hypo about herbal diabetes drug|last=Somasekhar|first=M.|website=@businessline|language=en|access-date=2018-12-15}}</ref>) is an ] drug, sold as an ] pill in India for management of ]. It was developed by two government-laboratories in 2015 and commercially launched in 2016.


The drug has been heavily criticized as a ]<ref>{{Cite web|url=https://thewire.in/media/pseudoscience-claims-bgr34-sanjeevani|title=Seven of the Fishiest 'Science' Claims Indians Made in 2016|website=The Wire|access-date=2018-12-18}}</ref> and the clinical efficacy of the drug remains unproven courtesy a dearth of any rigorous ].<ref name=":12">{{Cite book|url=https://books.google.co.in/books?id=ruBwDwAAQBAJ&lpg=PA110|title=Traditional Knowledge in Modern India: Preservation, Promotion, Ethical Access and Benefit Sharing Mechanisms|last=Sengupta|first=Nirmal|date=2018|publisher=Springer|isbn=9788132239222|language=en}}</ref> The manufacturers have refused to buy the claims of inefficacy and other raised concerns. The drug has been heavily criticized as a ]<ref>{{Cite web|url=https://thewire.in/media/pseudoscience-claims-bgr34-sanjeevani|title=Seven of the Fishiest 'Science' Claims Indians Made in 2016|website=The Wire|access-date=2018-12-18}}</ref> and the clinical efficacy of the drug remains unproven courtesy a dearth of any rigorous ].<ref name=":12">{{Cite book|url=https://books.google.co.in/books?id=ruBwDwAAQBAJ&lpg=PA110|title=Traditional Knowledge in Modern India: Preservation, Promotion, Ethical Access and Benefit Sharing Mechanisms|last=Sengupta|first=Nirmal|date=2018|publisher=Springer|isbn=9788132239222|language=en}}</ref> The manufacturers have refused to buy the claims of inefficacy and other raised concerns.

Revision as of 12:50, 9 January 2019

An Ayurvedic drug in India that supposedly treats Diabetes mellitus type 2

BGR-34 (Blood Glucose Regulator 34) is an Ayurvedic drug, sold as an over-the-counter pill in India for management of Diabetes mellitus type 2. It was developed by two government-laboratories in 2015 and commercially launched in 2016.

The drug has been heavily criticized as a sham treatment and the clinical efficacy of the drug remains unproven courtesy a dearth of any rigorous clinical trial. The manufacturers have refused to buy the claims of inefficacy and other raised concerns.

Development

The drug was jointly developed by two government laboratories, National Botanical Research Institute (NBRI) and Central Institute for Medicinal and Aromatic Plant (CIMAP) under the patronage of the Council of Scientific and Industrial Research (CSIR). The formulation was publicized in September 2015 as NBRMAP-DB and it was commercially launched by AIMIL Pharmaceuticals, in June 2016 priced at 5 INR (0.07 USD) per 500 milligram tablet which was to be consumed twice a day. CSIR has claimed it to be the first Indian ayurvedic anti-diabetic drug and the laboratories were awarded the CSIR Technology Award, 2016 in the Life Sciences category.

Constitution

The raw materials are derived from six plants:- Daruharidra, Giloy, Vijaysar, Gudmar, Manjeestha and Methi; all of which individually possess scientifically-vetted miscellaneous medicinal properties. They were claimed to be chosen from an 'in-depth study of over 500 renowned ancient herbs' pending which the ratios were optimized.

Ayurveda is a system of medicine with historical roots in the Indian subcontinent and practices derived from it form a type of alternative medicine. Whilst some researchers consider it to be pseudoscientific, others consider it a protoscience or trans-science system instead.

Pharmacological claims

The formulation claims to release 34 active phytoconstituents to work as a DPP-4 Inhibitor and thus, regulate blood glucose levels. CSIR had also claimed that the drug has several other side-benefits and can stave off dependency on insulin or other allopathic drugs.It was also advertised to not have any side-effects.A trial on animals had supposedly exhibited a success rate of ~67%.

A clinical trial in one of their own Ayurvedic hospitals involving 56 (48) patients was uploaded to Clinical Trials Registry of India (CTRI) months later and subsequently published in European Journal of Pharmaceutical and Medical Research, a predatory journal. It did neither show any pharmacokinetic data nor any mathematical result in the form of numbers or graph but minimally asserted the trial to ‘show promising results’ and that in light of the 'significant improvement in the feeling of wellbeing, it should be further extensively used as a monotherapy/adjunctive therapy'. The same results were also publicized by a group of researchers (five from AIMIL and three doctors from the hospital) in a November 2017 conference held by the OMICS Publishing Group under the ConferenceSeries banner. OMICS is near-unanimously held to be a predatory publisher with little to non-existent quality-control and their conferences have been subject to equivalent criticism.

The very same group of researchers (sans two of the doctors) ran a clinical-trial (which was claimed to have been conducted according to the Indian Council of Medical Research (ICMR) guidelines on conducting trials of ayurvedic substances) in 2018 and published the findings in the Journal of Traditional and Complementary Medicine. BGR-34 was determined to be successful in controlling the glycosylated haemoglobin levels of about 50% patients.Noticeable reduction in fasting blood glucose levels and postprandial glucose levels were also simultaneously observed.

Reception

Upon its launch as a 'scientifically validated' drug, which was approved by the Ministry of AYUSH, multiple media-units deemed it favorably and hailed it as a 'breakthrough-drug' especially in light of its supposedly cheap price. Claims of high clinical efficacy in multiple clinical and animal trials were reported from CSIR quarters. On the ceremony of the platinum jubilee of CSIR, Prime Minister Narendra Modi mentioned the drug as an achievement of the institution.

Criticism

The drug was subject to heavy criticism from multiple quarters.

There was initially a complete dearth of any published clinical trials of the drug and the claims of efficacy could not be any verified. No publications about any scientific research undertaken regarding the drug (about contraindication, toxicology et al.) can be located either. Despite being branded as an Ayurvedic product, there was no patent application at the National Botanical Research Institute (NBRI) corpus or the Intellectual property in India portal. The claims of BGR34 being cheaper than equivalent Allopathic drugs were also determined to be misleading. Physicians have noted safety-hazards from the usage of the drugand multiple side-effects have been reportedand it has been near-unanimously described to be inefficient by medical practitioners. Consumer reviews have been mixed, all throughout the years.

In October 2016, the Advertising Standards Council of India banned an advertisement of BGR-34 which claimed to ''cure Type 2 Diabetes Mellitus without any side effects''. It held the advertisement to not only violate the The Drugs & Magic Remedies Act by offering to cure an incurable disease but also under the purview of disseminating unsubstantiated claims without any corresponding data.

Mohan Nair, a veteran pharmaceutical scientist and advisor to National Task Force on Phyto-pharmaceuticals expressed his concern in exposing the populace to a drug not validated by any trial and about the potential hampering of the credibility of CSIR. Sankaran Valiathan, chairman of the Task Force on Ayurvedic Biology of the Department of Science and Technology criticized the CSIR on making unsubstantiated claims and releasing a drug without evaluating the safety and efficacy components. Ms Shailaja Chandra, former Secretary, Department of AYUSH, termed the entire fracas as something that can bring the entire Ayurveda and the research work done for long into disrepute.Avinash Bhondwe, senior vice-president of the Indian Medical Association commented that there was a absence of any comprehensive clinical study on most AYUSH drugs and urged the FDA to take measures.

A Lancet paper described the boom of alternative therapies for diabetes in India as a hype and pointed to multiple systemic reviews that highlighted several methodological problems with the studies and trials conducted by AYUSH and associates. It also criticized the ICMR guidelines that waived or relaxed the rules for rigorous pharmacological and toxicology studies for Ayurvedic products, provided that the medicines were “prepared in same way as mentioned in ancient Ayurvedic treatises".

In an article at Journal of Ayurveda and Integrative Medicine, Bhushan Patwardhan critiqued the Government regulations in these areas as lackadaisical and held it to be non-satisfactory as to ensuring the non-exploitation of the broader populace. He also noted a long-prevalent pattern of the CSIR investing efforts into launching multiple drugs with obscure scientific credentials that often fizzed off after a gala launch and described it to be primarily inept and with a potential to erode the credibility of Indian traditions and knowledge heritage. He also claimed that many senior scientists from CSIR were quite skeptical of such 'populistic and market driven propaganda' and the preference to undertake scientific research by the means of media-headlines rather than by publications in credible scientific journals were worrying. The concerns have been echoed in other quarters.

Response

Despite longstanding concerns and criticism, the CSIR has continued to hail it as a revolutionary innovation.In response to a question in Rajya Sabha, Shripad Naik, Union Minister of State, Ministry of AYUSH claimed that BGR-34 was ''scientifically tested and very effective in treating type 2 Diabetes'' and that the drug has been successful.

Dr Girish Sahni, Director General, CSIR in 2018 went on to claim the drug ''to match the efficacy level of any branded modern medicine'' and it was subsequently enlisted as a major achievement of CSIR under the current political regime.There have been an aggressive marketing of the drug and it has been inducted into the Anti-Diabetes Campaigns by Central and state authorities.

Similar drugs

Multiple anti-diabetic ayurvedic drugs have been developed and licensed to private industries, for production.

Central Council for Research in Ayurvedic Sciences (CCRAS), an autonomous body of the Ministry of AYUSH derived a second drug for diabetes called AYUSH-82 (containing five herbal ingredients:-Karela, Jamun, Amra, Gudmar and Shilajeet) from BGR-34. CCRAS scientists claimed that it permanently cures type-II-diabetes within a span of six months and that it had no side-effects. The distribution and manufacturing rights were granted to Kudos laboratories who subsequently re-branded it as IME9.

Similar criticisms about absence of rigorous pharmacological studies and lack of meaningful clinical trials (coupled with publications in dubious predatory journals) were noted.

References

  1. Somasekhar, M. "2 years on, markets still hypo about herbal diabetes drug". @businessline. Retrieved 2018-12-15.
  2. "Seven of the Fishiest 'Science' Claims Indians Made in 2016". The Wire. Retrieved 2018-12-18.
  3. ^ Sengupta, Nirmal (2018). Traditional Knowledge in Modern India: Preservation, Promotion, Ethical Access and Benefit Sharing Mechanisms. Springer. ISBN 9788132239222.
  4. ^ May 19, P. T. I.; May 19, 2018UPDATED:; Ist, 2018 15:35. "Herbal drug BGR-34 helps cutting down heart attack risk : study". India Today. Retrieved 2018-12-15. {{cite web}}: |first3= has numeric name (help)CS1 maint: extra punctuation (link) CS1 maint: numeric names: authors list (link)
  5. IANS (2017-03-22). "BGR-34 most cost-effective Ayurvedic medicine for diabetes". Mangalorean.com. Retrieved 2018-12-26.
  6. ^ "CSIR launches ayurvedic anti-diabetic drug BGR-34". @businessline. Retrieved 2018-12-18.
  7. ^ www.ETHealthworld.com. "Scientifically validated Rs 5 anti-diabetes herbal drug launched by CSIR - ET HealthWorld". ETHealthworld.com. Retrieved 2018-12-18.
  8. Pilla, Viswanath (2015-10-26). "Five rupee herbal pill to treat diabetes". livemint.com. Retrieved 2018-12-26.
  9. ^ "BGR-34 PRODUCT". pib.nic.in. Retrieved 2018-12-26.
  10. September 26, P. T. I.; September 26, 2016UPDATED:; Ist, 2016 20:20. "Govt announces recipients of Shanti Swarup Bhatnagar award". India Today. Retrieved 2018-12-26. {{cite web}}: |first3= has numeric name (help)CS1 maint: extra punctuation (link) CS1 maint: numeric names: authors list (link)
  11. ^ "Centre Approves Ayurvedic Drug – But Its Science is Missing". The Wire. Retrieved 2018-12-15.
  12. Meulenbeld, Gerrit Jan (1999). "Introduction". A History of Indian Medical Literature. Groningen: Egbert Forsten. ISBN 978-9069801247.
  13. Smith, Frederick M.; Wujastyk, Dagmar (2008). "Introduction". In Smith, Frederick M.; Wujastyk, Dagmar (eds.). Modern and Global Ayurveda: Pluralism and Paradigms. New York, NY: SUNY Press. pp. 1–28. ISBN 9780791478165. OCLC 244771011. {{cite book}}: Invalid |ref=harv (help)
  14. "A Closer Look at Ayurvedic Medicine". Focus on Complementary and Alternative Medicine. 12 (4). Fall 2005 – Winter 2006. Archived from the original on 2006-12-09.
  15. Semple D, Smyth R (2013). Chapter 1: Psychomythology (3rd ed.). Oxford University Press. p. 20. ISBN 978-0-19-969388-7. {{cite book}}: |work= ignored (help)
  16. Quack, Johannes (2011). Disenchanting India: Organized Rationalism and Criticism of Religion in India. Oxford University Press. pp. 213, 3. ISBN 9780199812608.
  17. Manohar, P. Ram (2009). "The blending of science and spirituality in the Ayurvedic healing tradition". In Paranjape, Makarand R. (ed.). Science, Spirituality and the Modernization of India. Anthem Press. pp. 172–3. ISBN 9781843317760.
  18. CHHABRA, RAHUL (2018-09-17). "Centre plans Ayurveda-for-diabetes campaign". The Asian Age. Retrieved 2018-12-16.
  19. ^ Shaikh, Dr Sumaiya (2017-08-13). "Are AYUSH supported BGR-34 and IME-9 drugs safe and effective for diabetes?". Alt News. Retrieved 2018-12-15.
  20. "BGR-34 – Aimil Pharmaceuticals". Retrieved 2018-12-15.
  21. ^ Pulla, Priyanka (2018-02-25). "Big claims, little evidence". The Hindu. ISSN 0971-751X. Retrieved 2018-12-16.
  22. "EJPMR | ABSTRACT". www.ejpmr.com. Retrieved 2018-12-15.
  23. "CTRI". ctri.nic.in. Retrieved 2018-12-15.
  24. Mansfield, Peter (2017). "Controlled clinical study of an Ayurvedic anti-diabetic formulation BGR-34 tablets for its efficacy and safety in patients with diabetes mellitus". Journal of Diabetes & Metabolism. 8 (10): 18. doi:10.4172/2155-6156-C1-072. ISSN 2155-6156.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  25. Declan Butler, "Investigating journals: The dark side of publishing", Nature, 27 March 2013
  26. "On the Net, a scam of a most scholarly kind" The Hindu, 26 September 2012.
  27. Beall, Jeffrey (2010-07-01). "Update: Predatory Open-Access Scholarly Publishers". The Charleston Advisor. Retrieved 2012-10-02.
  28. Beall, Jeffrey (13 October 2016). "Bogus British Company "Accredits" OMICS Conferences". Scholarly Open Access. Archived from the original on 6 November 2016. Retrieved 22 October 2016. {{cite web}}: Unknown parameter |deadurl= ignored (|url-status= suggested) (help)
  29. Hunt, Elle (22 October 2016). "Nonsense paper written by iOS autocomplete accepted for conference". The Guardian. Retrieved 22 October 2016.
  30. Spears, Tom (3 March 2017). "When pigs fly: Fake science conferences abound for fraud and profit". Ottawa Citizen.
  31. Spears, Tom (5 June 2017). "Fake science publisher offers shoddy continuing education for doctors, nurses". Ottawa Citizen.
  32. ^ Gupta, B.P.; Sharma, I.; Kohli, N.; Sharma, S.; Rathi, A.; Sharma, A.K. (2018-10-01). "Preliminary clinical assessment and non- toxicity evaluation of an ayurvedic formulation BGR-34 in NIDDM". Journal of Traditional and Complementary Medicine. 8 (4): 506–514. doi:10.1016/j.jtcme.2017.11.004. ISSN 2225-4110. PMC 6174273. PMID 30302331.
  33. "BGR-34: Herbal Anti- Diabetes Drug Launched by CSIR". www.clinicalresearchsociety.org. Retrieved 2018-12-15.
  34. Reddy, Prashant. "Innovation and Regulation of Ayurvedic medicine: CSIR's BGR-34, nimensulide in Ayurvedic medicine and other such stories". SpicyIP. Retrieved 2018-12-26.
  35. ^ www.ETHealthworld.com. "CSIR scientists develop BGR - 34, highly effective in Type 2 diabetes management - ET HealthWorld". ETHealthworld.com. Retrieved 2018-12-15.
  36. "CSIR launches ayurvedic anti-diabetic drug BGR-34 - Times of India". The Times of India. Retrieved 2018-12-15.
  37. ^ www.ETHealthworld.com. "CSIR'S anti-diabetic drug: Did it deserve Modi's praise? - ET HealthWorld". ETHealthworld.com. Retrieved 2018-12-15.
  38. ^ "Ad promoting 'miracle' ayurvedic drug for diabetes taken off air - Times of India". The Times of India. Retrieved 2018-12-15.
  39. Patwardhan, B. (2016-07-01). "Ayurvedic drugs in case: Claims, evidence, regulations and ethics". Journal of Ayurveda and Integrative Medicine. 7 (3): 135–137. doi:10.1016/j.jaim.2016.08.005. ISSN 0975-9476. PMC 5052386. PMID 27640330.
  40. From a legal perspective, the Drugs & Cosmetics Act do not mandate any clinical trial for Ayurvedic medications except for a guarantee of non-toxicity but for allopathic drugs, phase 3 trials must include at-least 500 patients spanned across multiple centers.
  41. ^ "Did CSIR's Anti-Diabetic Drug Deserve Modi's Praise?". The Wire. Retrieved 2018-12-15.
  42. "CSIR unveils herbal anti-diabetes drug 'BGR-34' priced very high; no clinical trails conducted". The TeCake. 2015-10-27. Retrieved 2018-12-26.
  43. "What is AYUSH and the controversy around it?". Deccan Herald. 2018-11-20. Retrieved 2018-12-15.
  44. Sridhar, Narsing Rao (2015-12-25). "Ayurvedic Diabetes drug BGR 34 Side Effects Surface Slowly". Microfinance Monitor. Retrieved 2018-12-15.
  45. Chandna, Himani (14 December 2018). "Modi govt's love for Ayurveda may be undermining ancient medicinal system". The Print. Retrieved 18 December 2018.
  46. "ASCI bans 134 ads, including Himalaya, HUL, GSK, M&M, Airtel, Policybazaar, BGR-34 capsules and Tata Docomo in July". Moneylife NEWS & VIEWS. Retrieved 2018-12-18.
  47. ^ Patwardhan, Bhushan (2016). "Ayurvedic drugs in case: Claims, evidence, regulations and ethics". Journal of Ayurveda and Integrative Medicine. 7 (3): 135–137. doi:10.1016/j.jaim.2016.08.005. PMID 27640330.
  48. Misra, Anoop; Gulati, Seema; Luthra, Atul (2016). "Alternative medicines for diabetes in India: Maximum hype, minimum science". The Lancet Diabetes & Endocrinology. 4 (4): 302–303. doi:10.1016/S2213-8587(15)00515-X. PMID 27016323. {{cite journal}}: Cite has empty unknown parameter: |dead-url= (help)
  49. "New herbal drug developed by CSIR promises better management of diabetes - Times of India". The Times of India. Retrieved 2018-12-18.
  50. "Whip looms on misleading ayurveda ads". www.telegraphindia.com. Retrieved 2018-12-25.
  51. "PressReader.com - Connecting People Through News". www.pressreader.com. Retrieved 2018-12-15.
  52. "CSIR invention BGR-34 enlisted as major achievement in Delhi". dna. 2018-06-14. Retrieved 2018-12-15.
  53. Pioneer, The. "'Madhumeha through Ayurveda' Mission going good". The Pioneer. Retrieved 2018-12-16.
  54. "Patients are switching to herbal medicines for diabetes". dna. 2018-09-29. Retrieved 2018-12-16.
Categories: